PolyPeptide Group AG
Symbol: PPGN.SW
SIX
30.85
CHFMarknadspris idag
-20.2164
P/E-tal
-0.4777
PEG-kvot
1.02B
MRK Aktiekapital
- 0.00%
DIV Avkastning
{{företagets_namn}} (PPGN-SW) Finansiella rapporter
Balansräkning
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |||
---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 208.66 | 95.7 | 37.5 | 136.3 | ||||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | ||||||
balance-sheet.row.net-receivables | 279.04 | 101.1 | 49.1 | 67.8 | ||||||
balance-sheet.row.inventory | 564.08 | 128.5 | 145.1 | 113 | ||||||
balance-sheet.row.other-current-assets | 71.69 | 1.3 | 19.8 | 14.5 | ||||||
balance-sheet.row.total-current-assets | 1123.47 | 326.6 | 251.6 | 331.6 | ||||||
balance-sheet.row.property-plant-equipment-net | 1190.14 | 324.1 | 297.3 | 235.4 | ||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||
balance-sheet.row.intangible-assets | 63.7 | 16.5 | 15.9 | 14.3 | ||||||
balance-sheet.row.goodwill-and-intangible-assets | 63.7 | 16.5 | 15.9 | 14.3 | ||||||
balance-sheet.row.long-term-investments | 13.32 | 5.2 | 2.8 | 3.5 | ||||||
balance-sheet.row.tax-assets | 42.61 | 16.7 | 8.3 | 10.3 | ||||||
balance-sheet.row.other-non-current-assets | -25.92 | 0 | -8.3 | -10.3 | ||||||
balance-sheet.row.total-non-current-assets | 1283.86 | 362.5 | 315.9 | 253.2 | ||||||
balance-sheet.row.other-assets | 25.92 | 0 | 8.3 | 10.3 | ||||||
balance-sheet.row.total-assets | 2433.25 | 689.1 | 575.8 | 595 | ||||||
balance-sheet.row.account-payables | 160.69 | 60.9 | 45.9 | 28.5 | ||||||
balance-sheet.row.short-term-debt | 111.1 | 45.7 | 3.6 | 3.1 | ||||||
balance-sheet.row.tax-payables | 17.52 | 9.3 | 4.9 | 7.6 | ||||||
balance-sheet.row.long-term-debt-total | 97 | 68 | 9.4 | 10.3 | ||||||
Deferred Revenue Non Current | 47.26 | 23.2 | 7.5 | 9.2 | ||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 8.59 | - | - | - | ||||||
balance-sheet.row.other-current-liab | 237.3 | 1.4 | 50.1 | 75.5 | ||||||
balance-sheet.row.total-non-current-liabilities | 160.46 | 131.4 | 9.4 | 10.3 | ||||||
balance-sheet.row.other-liabilities | 146.11 | 0 | 48.6 | 59.6 | ||||||
balance-sheet.row.capital-lease-obligations | 87.25 | 23.3 | 21.2 | 18 | ||||||
balance-sheet.row.total-liab | 818.72 | 307.9 | 154.1 | 173.9 | ||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||
balance-sheet.row.common-stock | 1.21 | 0.3 | 0.3 | 0.3 | ||||||
balance-sheet.row.retained-earnings | 775.36 | 165.1 | 214.1 | 196 | ||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 74.69 | 23 | 17.7 | 13.2 | ||||||
balance-sheet.row.other-total-stockholders-equity | 763.27 | 192.7 | 189.5 | 211.6 | ||||||
balance-sheet.row.total-stockholders-equity | 1614.53 | 381.2 | 421.7 | 421.2 | ||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 2433.25 | 689.1 | 575.8 | 595 | ||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||||
balance-sheet.row.total-equity | 1614.53 | 381.2 | 421.7 | 421.2 | ||||||
balance-sheet.row.total-liabilities-and-total-equity | 2433.25 | - | - | - | ||||||
Total Investments | 13.32 | 5.2 | 2.8 | 3.5 | ||||||
balance-sheet.row.total-debt | 232.77 | 113.7 | 21.2 | 18 | ||||||
balance-sheet.row.net-debt | 24.11 | 18 | -16.3 | -118.3 |
Kassaflödesanalys
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |||
---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -43.67 | -51.4 | 7.8 | 47.3 | ||||||
cash-flows.row.depreciation-and-amortization | 49.47 | 30.5 | 24 | 18.7 | ||||||
cash-flows.row.deferred-income-tax | 46.42 | 3.1 | 13.2 | 28.7 | ||||||
cash-flows.row.stock-based-compensation | 2.05 | 0.8 | 1.2 | 1.2 | ||||||
cash-flows.row.change-in-working-capital | -29.34 | 46.2 | -14.3 | -29.9 | ||||||
cash-flows.row.account-receivables | -10.56 | 0 | 18.8 | -12.2 | ||||||
cash-flows.row.inventory | -17.62 | 15.5 | -33.1 | -17.7 | ||||||
cash-flows.row.account-payables | 0 | 0 | 0 | 0 | ||||||
cash-flows.row.other-working-capital | -1.16 | 30.7 | 0 | 0 | ||||||
cash-flows.row.other-non-cash-items | 63.45 | 7.3 | -26.3 | -8.6 | ||||||
cash-flows.row.net-cash-provided-by-operating-activities | 41.95 | 0 | 0 | 0 | ||||||
cash-flows.row.investments-in-property-plant-an-equipment | -128 | -56.7 | -75.1 | -74 | ||||||
cash-flows.row.acquisitions-net | 0 | 0 | 0 | 0 | ||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | ||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | ||||||
cash-flows.row.other-investing-activites | -9.95 | -2.8 | -3.3 | -6.9 | ||||||
cash-flows.row.net-cash-used-for-investing-activites | -137.95 | -59.5 | -78.4 | -80.8 | ||||||
cash-flows.row.debt-repayment | -3.51 | -55.2 | -3.3 | -41.4 | ||||||
cash-flows.row.common-stock-issued | 13.79 | 0 | 17.2 | 182.1 | ||||||
cash-flows.row.common-stock-repurchased | -13.93 | 0 | -13.9 | -5.5 | ||||||
cash-flows.row.dividends-paid | -9.67 | 0 | -9.7 | -135.3 | ||||||
cash-flows.row.other-financing-activites | 71.01 | 139.7 | -17.2 | 130.9 | ||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 57.68 | 84.5 | -26.9 | 130.9 | ||||||
cash-flows.row.effect-of-forex-changes-on-cash | -2.27 | -3.3 | 1.1 | 11.7 | ||||||
cash-flows.row.net-change-in-cash | -40.6 | 58.2 | -98.8 | 119.1 | ||||||
cash-flows.row.cash-at-end-of-period | 208.66 | 95.7 | 37.5 | 136.3 | ||||||
cash-flows.row.cash-at-beginning-of-period | 249.25 | 37.5 | 136.3 | 17.2 | ||||||
cash-flows.row.operating-cash-flow | 41.95 | 36.5 | 5.5 | 57.4 | ||||||
cash-flows.row.capital-expenditure | -128 | -56.7 | -75.1 | -74 | ||||||
cash-flows.row.free-cash-flow | -86.05 | -20.2 | -69.6 | -16.6 |
Resultaträkning rad
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |||
---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 601.35 | 320.4 | 281 | 282.1 | ||||||
income-statement-row.row.cost-of-revenue | 544.59 | 315.7 | 229 | 182.4 | ||||||
income-statement-row.row.gross-profit | 56.76 | 4.6 | 52 | 99.7 | ||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||
income-statement-row.row.research-development | 2.71 | - | - | - | ||||||
income-statement-row.row.selling-general-administrative | 70.54 | - | - | - | ||||||
income-statement-row.row.selling-and-marketing-expenses | 8.96 | - | - | - | ||||||
income-statement-row.row.other-expenses | 0 | 0 | 0 | 0 | ||||||
income-statement-row.row.operating-expenses | 99.79 | 41.1 | 42.3 | 37 | ||||||
income-statement-row.row.cost-and-expenses | 644.37 | 356.8 | 271.3 | 219.5 | ||||||
income-statement-row.row.interest-income | 8.77 | 0.1 | 2.1 | 2.8 | ||||||
income-statement-row.row.interest-expense | 0 | 5.6 | 2.1 | 2.8 | ||||||
income-statement-row.row.selling-and-marketing-expenses | 8.96 | - | - | - | ||||||
income-statement-row.row.total-other-income-expensenet | -29.37 | -21.8 | -5 | -7.6 | ||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||
income-statement-row.row.other-operating-expenses | 0 | 0 | 0 | 0 | ||||||
income-statement-row.row.total-operating-expenses | -29.37 | -21.8 | -5 | -7.6 | ||||||
income-statement-row.row.interest-expense | 0 | 5.6 | 2.1 | 2.8 | ||||||
income-statement-row.row.depreciation-and-amortization | 42.05 | 30.5 | 20.5 | 16.1 | ||||||
income-statement-row.row.ebitda-caps | 20.74 | - | - | - | ||||||
income-statement-row.row.operating-income | -21.3 | -36.5 | 12.5 | 67.4 | ||||||
income-statement-row.row.income-before-tax | -50.68 | -58.2 | 7.6 | 59.8 | ||||||
income-statement-row.row.income-tax-expense | 12.19 | -6.8 | 0.2 | 12.6 | ||||||
income-statement-row.row.net-income | -43.67 | -51.4 | 7.8 | 47.3 |
Ofta ställda frågor
Vad är PolyPeptide Group AG (PPGN.SW) totala tillgångar?
PolyPeptide Group AG (PPGN.SW) totala tillgångar är 689088000.000.
Vad är företagets årliga omsättning?
Den årliga intäkten är 320372000.000.
Vad är företagets vinstmarginal?
Företagets vinstmarginal är 0.015.
Vad är företagets fria kassaflöde?
Fritt kassaflöde är -0.498.
Vad är företagets nettovinstmarginal?
Nettovinstmarginalen är -0.161.
Vad är företagets totala intäkter?
Totala intäkter är -0.106.
Vad är PolyPeptide Group AG (PPGN.SW) nettovinst (nettoinkomst)?
Nettovinst (nettoinkomst) är -51440000.000.
Vad är företagets totala skuldsättning?
Den totala skulden är 113662000.000.
Vad är rörelsens kostnader?
Rörelsens kostnader är 41110000.000.
Vad är företagets kassaflöde?
Företagets kassa är 95706000.000.